Abbott Laboratories announced that its Precision Oncology portfolio will be integrated into Flatiron Health’s cloud‑based OncoEMR electronic medical record platform, allowing oncology providers to order Abbott’s tests—Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard—directly within Flatiron’s workflow and receive results in real time.
The integration covers Flatiron’s national network of more than 1,600 community cancer care centers and 4,700 providers, removing a key barrier to point‑of‑care access and accelerating treatment decisions across the U.S. cancer care continuum.
This move follows Abbott’s completion of the Exact Sciences acquisition on March 23, 2026, which added approximately $3 billion in incremental sales for 2026 and is expected to dilute adjusted EPS by about $0.20. The integration expands Abbott’s reach into the high‑margin oncology diagnostics market, complementing its existing cancer screening products and supporting its strategy to grow the oncology diagnostics platform.
By embedding the tests into Flatiron’s workflow, Abbott reduces administrative friction for oncologists, enabling faster ordering and quicker receipt of results. The expanded access is expected to increase test volumes and revenue, reinforcing Abbott’s outlook of 6.5%–7.5% organic sales growth and adjusted diluted EPS of $5.55 to $5.80 for 2026.
“By integrating Abbott’s Precision Oncology portfolio directly into OncoEMR, we’re reducing friction in the workflow and helping providers move faster – from test ordering to treatment decisions,” said Quincy Weatherspoon, VP and GM of Point of Care Solutions at Flatiron Health. “The integration ‘removes a key barrier to accessing our portfolio at the point of care,’” added Brian Baranick, VP of Precision Oncology at Abbott.
While no specific market reaction to the integration was reported, the announcement comes amid Abbott’s recent strategic activity, including the Exact Sciences acquisition and a focus on expanding its oncology diagnostics footprint.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.